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Reduced-Intensity Stem Cell Allografting for PNH
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Background: Paroxysmal nocturnal haemoglobinuria (PNH)
presents as two major entities: the classical form, predomi-
nantly hemolytic, and a secondary type with marrow failure
and resultant aplastic anaemia (AA-PNH). Currently, the
treatment of choice of the hemolytic variant is eculizumab;
however, the most frequent form of PNH in México is AA-
PNH.
Patients and Methods: Six consecutive AA-PNH patients
with HLA-identical siblings were allografted in two in-
stitutions in México, employing a reduced-intensity condi-
tioning regimen for stem cell transplantation (RIST)
conducted on an outpatient basis.Figure 1. (A) Percent reduction in LN size, reported as sum of the product of LN diame
of WBCs) and blood donor CD3 chimerism for SPN3975 and(C) SPN3431. (D) B cells
molecules and unique IgH clone counts for SPN3975 at time points (D¼day) post allResults: Median age of the patients was 37 years (range
25e48). The patients were given a median of 5.4  106/kg
allogeneic CD34(+) cells, using 1e3 apheresis procedures.
Median time to achieve above 0.5  109/l granulocytes was
21 days, whereas median time to achieve above 20  109/l
platelets was 17 days. Five patients are alive for 330e3150
days (median 1437) after the allograft. The 3150-day overall
survival is 83.3%, whereas median survival has not been
reached, being above 3150 days.
Conclusion: We have shown that hypoplastic PNH pa-
tients can be allografted safely using RIST and that the
long-term results are adequate, the costebeneﬁt ratio of
this treatment being reasonable. Additional studies are
needed to conﬁrm the usefulness of RIST in the treatment
of AA-PNH.
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(excluding the CLL clone) as percent of total PBMC for SPN3975. (E) Total IgH
o-HCT.
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lymphocytic leukemia (CLL) with ibrutinib results in high
rates of progression-free and overall survival. Ibrutinib, an
irreversible Bruton’s tyrosine kinase inhibitor, may also
modulate donor T cell alloimmunity via interleukin-2-
inducible kinase inhibition. We report results of ibrutinib
salvage therapy in 5 high risk CLL patients who relapsed
following allogeneic hematopoietic cell transplantation
(allo-HCT). Lymph node (LN) size was measured by CT
scan, CLL minimal residual disease (MRD) levels by IgH
high-throughput sequencing (HTS) (ClonoSIGHTTM test,
Sequenta Inc.), donor CD3 chimerism by short tandem
repeat analysis, and donor B cell immune reconstitution
by IgH HTS quantiﬁcation of total IgH molecules and
unique IgH clonotypes.
Results: All 4 patients with pathologic lymphadenopathy
prior to treatment experienced dramatic LN reduction on
ibrutinib (Fig 1A; 68% average reduction after 3 mos). Pa-
tients SPN3975 (17p del) and SPN3431 (11q del) achieved
undetectable CLL MRD (<10-6) after 39 mos and 8 mos,
respectively (Fig 1B, 1C). SPN3975 had failed to maintain full
donor CD3 chimerism after dose-escalated donor lympho-
cyte infusions but after 1 yr of ibrutinib achieved full donor
chimerism. Oral and skin chronic graft-versus-host disease
(cGVHD) additionally resolved after 6 mos. Two additional
patients have increased donor chimerism since starting
ibrutinib. Although SPN3975 has not taken ibrutinib for >10
mos, full donor chimerism persists and CLL MRD remains
undetectable (Fig 1B). Prior to ibrutinib, donor B cells in this
patient (excluding the CLL clone) accounted for<0.2% of total
PBMC. Following discontinuation of ibrutinib, donor B cells
increased within 6 mos and now comprise >1% of PBMC (Fig
1D). Furthermore, recovering B cells have diverse, low fre-
quency IgH clonotypes (Fig 1E).
Conclusions: Ibrutinib provides effective salvage therapy for
CLL relapse following allo-HCT and demonstrates promising
donor immune modulation, promoting full donor chimerism
and cGVHD resolution. Here we present 2 post allo-HCT CLL
relapse patients who achieved MRD negativity on ibrutinib,
one of whom maintains undetectable CLL 10 mos after
stopping therapy. Our ﬁndings show rapid, sustained, and
diverse immune reconstitution without CLL recurrence
following discontinuation. Clinical trials are needed to
determine the duration of therapy for post allo-HCT relapse,
role of ibrutinib maintenance, and cGVHD treatment efﬁcacy.Figure. 3-yr DFS after DCBT in children with high-risk acute leukemia445
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Introduction: DCBT in children with acute leukemia is
controversial given the ﬁndings of the recent BMT CTN ran-
domized study. However, many children will not have
adequate single-units based on the recent CIBMTR analysis
(cryopreserved TNC > 3.0 x 107/kg and 6-8/8 allele donor-
recipient HLA-match).
Methods: We analyzed 35 consecutive pediatric DCBT pa-
tients (pts) treated for acute leukemia (10/2005-2/2013). All
CBT recipients in this period received 2 units.
Results: Median pt age was 7.5 yrs (range 0.8-18), median
weight was 28 kg (range 8-75), and 69% had non-European
ancestry. Seventeen pts had AML: 6 CR1 (one each with M7,
secondary 5q- MDS, FLT-3 ITD, Ph+, Down syndrome MRD+,
germline mutation CEBPa), 8 CR2 (one MLL MRD+), 1 CR3,
and 2 in aplasia. Seventeen pts had ALL: 10 CR1 [3 Ph+ (one
MRD+), 2 T-cell ALL, 1 MLL, 1 L3 disease, and 3 multiple
inductions], 4 CR2, 3 CR3. One pt had advanced CML. Con-
ditioning was Cy120/Flu/TBI1375 (N ¼ 21, 60%) or chemo-
therapy-only (N ¼ 14, 40%, 10 Clo/Mel/Thio, 4 Bu/Mel/Thio).
GVHD prophylaxis was CNI/MMF. Units had a high degree of
donor-recipient HLA-allele disparity (Table). The cumulative
incidence of sustained donor neutrophil engraftment was
94% (95%CI:78-98, median 21 days, range 12-33), and he-
matopoiesis was mediated by a single unit. Day +180 platelet
engraftment  50 x 109/l was 82% (95%CI: 64-92, median 51
days, range 39-299). CD4+ count recovery was prompt: mean
day 60 201 (SD:+/-180), and day 120 250 (SD:+/-150). Of 33
engrafted pts, 10 (30%) engrafted with a unit with pre-
cryopreservation TNC < 2.5 x 107/kg, and 17 (51%) engrafted
with a unit  5/8 HLA-allele matched. The cumulative inci-
dence of day 100 grade II-IV acute GVHDwas 46% (95%CI:29-
61), and 23% (95%CI:11-38) had grade III-IV acute GVHD.
3-year chronic GVHD was 14% (95%CI:5-28). With a median
58 month (range 20-105) follow-up, the 3-year cumulative
incidence of TRM was 11% (95%CI:4-24); deaths were due to
graft failure (2), HHV-6 encephalitis (1), and viral pneumonia
(1). Relapse at 3 years was 20% (95%CI:9-35): 2 AML CR1 (one
FLT-3 ITD, one M7), one previously refractory AML, and 4 ALL
(2 CR1, 1 CR2, 1 CR3). None of the 4 pts transplanted with
MRD+ relapsed. Three-year DFS was 68% (95%CI:50-81), with
no difference based on diagnosis (p¼ 0.25, Figure), TBI-based
cytoreduction (p ¼ 0.68), or non-European ancestry (p ¼
0.24).
